The H2 allele of apolipoprotein (apo) C-I is associated with Alzheimer's disease (AD). However, this association is potentially confounded by the linkage disequilibrium of H2 with the ⑀2 and ⑀4 alleles of apoE and of H1 with the ⑀3 allele. To establish plausibility for a direct role for apoC-I in AD, we compared apoC-I and apoE protein and mRNA levels in postmortem specimens of frontal cortex and hippocampus from AD patients with levels in nondemented controls. In H2-allelic individuals (usually also ⑀4 carriers), apoC-I mRNA levels were strikingly lower with AD (by 65%, P < 0.05), but apoC-I protein levels in AD were significantly higher (by 34%, P < 0.05). The opposite direction of the apoC-I mRNA and apoC-I protein level changes in AD in the ⑀4/H2 genotype may reflect decreased clearance of CNS lipoproteins associated with apoE4. In H1/H1 (usually ⑀3/⑀3) individuals, both apoC-I protein and mRNA were lower in AD. ApoC-I protein levels in hippocampus were nearly twice those in frontal cortex. Immunohistochemistry of hippocampus revealed colocalization of apoC-I protein with the astrocytic marker GFAP. In addition, cultured human astrocytes expressed the mRNA for apoC-I. This study confirms apoC-I expression in the CNS and identifies astrocytes as the source of apoC-I. In addition, it has revealed differences in apoC-I expression based on site, genotype, and disease status that may reflect a role for apoC-I in the pathogenesis of AD.
INTRODUCTION
The biology of sporadic late-onset Alzheimer's disease (AD) remains incompletely understood. The powerful effect of genetic variation in apolipoprotein (apo) E, a lipid transport protein, in determining the risk of AD has focused attention on lipid trafficking in the central nervous system (CNS) as an important pathway in AD pathogenesis ((Poirier et al., 1993; Strittmatter et al., 1993; Saunders et al., 1993) . However, genetic linkage disequilibrium of the diseaseassociated allele of apoE, ⑀4, to a pathogenic allele of a gene in close proximity has not been excluded as a mechanism. ApoC-I is located adjacent to apoE in the Chromosome 19 apolipoprotein gene cluster and is a candidate for such a gene (Das et al., 1985; Knott et al., 1984a; Davison et al., 1986) . ApoC-I has been shown to block the interaction of apoE with all of its known receptors and, consequently, to delay the clearance of apoE-containing lipoproteins (Kowal et al., 1990; Weisgraber et al., 1990; Sehayek and Eisenberg, 1991; Shachter et al., 1996; Jong et al., 1998 Jong et al., , 1999a Jong et al., , 1999b .
